{
  "id": 13042632,
  "title": "Retension Pharmaceuticals Prices $45 Million IPO At $12 Per Share",
  "url": "https://urgent.news/2026/10/09/retension-pharmaceuticals-prices-45-million-ipo-at-12-per-share",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T04:40:37.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/retension-pharmaceuticals-prices-45-million-ipo-12-share"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Retension Pharmaceuticals, Inc. (RTSN), a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, announced the pricing of its upsized initial public offering of 3.75 million shares at $12.00 per share. Retension Pharmaceuticals i",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "TRexBio prices IPO at $14 per share, expects $116.7M",
        "url": "https://urgent.news/2026/10/09/trexbio-prices-ipo-at-14-per-share-expects-116-7m",
        "published": "2026-10-09T01:36:29.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}